ReviewExpert opinion on investigational drugs2016
Investigational drugs to treat methicillin-resistant Staphylococcus aureus.
Review in Expert opinion on investigational drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Advances in deep learning for antimicrobial research.Frontiers in microbiology · 2026Review
- Baohuoside I targets SaeR as an antivirulence strategy to disrupt MRSA biofilm formation and pathogenicity.NPJ biofilms and microbiomes · 2025Article
- Understanding the burden and impact of methicillin-resistantFrontiers in public health · 2025Article
- Exploiting the synergistic antibacterial activity of shikimic acid and ceftiofur against methicillin-resistant Staphylococcus aureus.World journal of microbiology & biotechnology · 2024Article
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- QSAR Studies, Synthesis, and Biological Evaluation of New Pyrimido-Isoquinolin-Quinone Derivatives against Methicillin-ResistantPharmaceuticals (Basel, Switzerland) · 2023Article
- Review
- Article
- Antibacterial activities of plant-derived xanthones.RSC medicinal chemistry · 2022Review
- 2,3-Dehydrokievitone combats methicillin-resistantFrontiers in microbiology · 2022Article
- Neuroprotective Effect ofFrontiers in neuroscience · 2022Article
- A random forest model based on core genome allelic profiles of MRSA for penicillin plus potassium clavulanate susceptibility prediction.Microbial genomics · 2021Article
- Research Progress on Antibacterial Activities and Mechanisms of Natural Alkaloids: A Review.Antibiotics (Basel, Switzerland) · 2021Review
- Involvement of caspase-1 in inflammasomes activation and bacterial clearance in S. aureus-infected osteoblast-like MG-63 cells.Cellular microbiology · 2020Article
- Antimicrobial potential of endophytic fungi from3 Biotech · 2019Article
- Antibiotic Resistance and the MRSA Problem.Microbiology spectrum · 2019Review
- Sulfide Protects Staphylococcus aureus from Aminoglycoside Antibiotics but Cannot Be Regarded as a General Defense Mechanism against Antibiotics.Antimicrobial agents and chemotherapy · 2018Article
- DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data.Microbiome · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionStaphylococcus aureus remains one of the leading causes of morbidity and mortality worldwide. This is to a large extent due to antibiotic-resistant strains, in particular methicillin-resistant S. aureus (MRSA). While the toll of invasive MRSA infections appears to decrease in U.S. hospitals, the rate of community-associated MRSA infections remains constant and there is a surge of MRSA in many other countries, a situation that calls for continuing if not increased efforts to find novel strategies to combat MRSA infections. AREAS COVERED: This review provides an overview of current investigational drugs and therapeutic antibodies against S. aureus in early clinical development (up to phase II clinical development). It includes a short description of the mechanism of action and a presentation of microbiological and clinical data. EXPERT OPINION: Increased recent antibiotic development efforts and results from pathogenesis research have led to several new antibiotics and therapies, such as anti-virulence drugs, as well as a more informed selection of targets for vaccination efforts against MRSA. This developing portfolio of novel anti-staphylococcal drugs will hopefully provide us with additional and more efficient ways to combat MRSA infections in the near future and prevent us from running out of treatment options, even if new resistances arise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.